New research may enhance the treatment for blood cancer in children
Acute lymphatic leukaemia is the most common form of blood cancer in children. Even though chemotherapy is improving, the cancer often returns. Johan Jansson's research at Kalmar University in Sweden shows that cancer cells that have been exposed to chemotherapy and survived are less vulnerable to chemotherapy, and more aggressive as well. But this research also yielded discoveries that should be able to enhance our treatment of the disease.
Johan Jansson's research shows that leukaemia cells that have been exposed to chemotherapy and survived did not develop resistance against bone marrow transplants from a sibling, for example. At the same time, however, several important changes were observed in these cancer cells. On the one hand, they were less vulnerable to chemotherapy and, on the other, their growth rate increased.
Johan Jansson also identified several immunologically important genes that either increased or decreased when they had been exposed to a bone marrow transplant. Three of these genes were especially interesting in that they were involved in activating the immune defence and the killing of cancer cells. It was also shown that such a bone marrow transplant could have an inhibiting effect on the leukaemia cells that also proved to be able to activate parts of the immune defence.
Finally, Johan Jansson studied whether it is possible to check the leukaemia cells that remain after a bone marrow transplant. This was done by vaccinating mice with a mixture of 'dead' leukaemia cells and immune cells from a donor. It was observed that the immune defence was activated to some degree, but that the mice did not live any longer as a result. On the other hand, it was seen that these mice had B cells that produced antibodies against leukaemia cells. This knowledge could be further elaborated to develop and enhance the effects of a bone marrow transplant.
Source: Kalmar University
